$16.60
+1.67 (+11.19%)
Open$15.26
Previous Close$14.93
Day High$16.65
Day Low$15.00
52W High$36.58
52W Low$16.46
Volume—
Avg Volume540.1K
Market Cap262.70M
P/E Ratio38.27
EPS$0.80
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+98.3% upside
Current
$16.60
$16.60
Target
$32.91
$32.91
$27.78
$32.91 avg
$47.11
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 35.20M | 36.29M | 36.66M |
| Net Income | 7.89M | 8.09M | 8.22M |
| Profit Margin | 22.4% | 22.3% | 22.4% |
| EBITDA | 9.70M | 9.50M | 9.77M |
| Free Cash Flow | 3.72M | 4.67M | 3.24M |
| Rev Growth | -4.5% | +16.8% | -1.1% |
| Debt/Equity | 0.47 | 0.47 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |